Patent intelligence · US
US 12409206
Use of cyclosporine analogues for treating fibrosis
Use of cyclosporine analogues for treating fibrosis
Patent details — US 12409206
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 9, 2025
- Expiration
- Sep 4, 2045
- Applicant
- Hepion Pharmaceuticals, Inc.
- Claims
- 19
- CPC classes
- A61K, A61K38/13, A61K45/06, A61P
Quick answer
US 12409206 (Use of cyclosporine analogues for treating fibrosis) is held by Hepion Pharmaceuticals, Inc.. Status: granted. Granted Sep 9, 2025. Expires Sep 4, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Hepion Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K38/13, A61K45/06, A61P, A61P1/16, A61P11/00
Frequently asked questions
What is US patent 12409206?
US 12409206 (Use of cyclosporine analogues for treating fibrosis) is held by Hepion Pharmaceuticals, Inc.. Status: granted. Granted Sep 9, 2025. Expires Sep 4, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12409206?
Hepion Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 12409206 expire?
Our index shows an expiration date of Sep 4, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.